---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:16:22.427683'
end_time: '2025-12-14T17:21:37.215324'
duration_seconds: 314.79
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: SOCS5
  gene_symbol: SOCS5
  uniprot_accession: O75159
  protein_description: 'RecName: Full=Suppressor of cytokine signaling 5; Short=SOCS-5;
    AltName: Full=Cytokine-inducible SH2 protein 6; Short=CIS-6; AltName: Full=Cytokine-inducible
    SH2-containing protein 5;'
  gene_info: Name=SOCS5; Synonyms=CIS6, CISH5, CISH6, KIAA0671;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: SH2. (IPR000980); SH2_dom_sf. (IPR036860); SOCS4/SOCS5_dom. (IPR022252);
    SOCS5_SOCS. (IPR037343); SOCS_box. (IPR001496)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 12
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O75159
- **Protein Description:** RecName: Full=Suppressor of cytokine signaling 5; Short=SOCS-5; AltName: Full=Cytokine-inducible SH2 protein 6; Short=CIS-6; AltName: Full=Cytokine-inducible SH2-containing protein 5;
- **Gene Information:** Name=SOCS5; Synonyms=CIS6, CISH5, CISH6, KIAA0671;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** SH2. (IPR000980); SH2_dom_sf. (IPR036860); SOCS4/SOCS5_dom. (IPR022252); SOCS5_SOCS. (IPR037343); SOCS_box. (IPR001496)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SOCS5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SOCS5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SOCS5** (gene ID: SOCS5, UniProt: O75159) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O75159
- **Protein Description:** RecName: Full=Suppressor of cytokine signaling 5; Short=SOCS-5; AltName: Full=Cytokine-inducible SH2 protein 6; Short=CIS-6; AltName: Full=Cytokine-inducible SH2-containing protein 5;
- **Gene Information:** Name=SOCS5; Synonyms=CIS6, CISH5, CISH6, KIAA0671;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** SH2. (IPR000980); SH2_dom_sf. (IPR036860); SOCS4/SOCS5_dom. (IPR022252); SOCS5_SOCS. (IPR037343); SOCS_box. (IPR001496)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SOCS5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SOCS5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SOCS5** (gene ID: SOCS5, UniProt: O75159) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human SOCS5 (UniProt O75159)

Verification of identity and domains
- Symbol and name: SOCS5 (Suppressor of cytokine signaling 5), also known as CIS-6/CISH6, matches the target protein identity given. SOCS proteins share a central SH2 domain and a C‑terminal SOCS box that recruits Elongin B/C to assemble a Cullin‑5–Rbx2 E3 ubiquitin ligase (CRL5), consistent with the UniProt-annotated domains for SOCS5 (SH2 and SOCS box) (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).
- Organism: Evidence cited below pertains to human SOCS proteins and SOCS5 function in mammalian systems; disease studies specifically use human tissues/cells or clinically relevant models (sun2024socs5targetedby pages 5-9, ghalehbaghi2024suppressorofcytokine pages 9-10, lynch2024unravellingthedruggability pages 13-15).
- Family/domain alignment: Reviews covering SOCS family architecture confirm SOCS5 carries the canonical SH2 and SOCS box; SOCS4/5 are particularly implicated in regulation of receptor tyrosine kinase (RTK) signaling, including EGFR, in addition to cytokine pathways (cianciulli2024inflammatoryskindiseases pages 3-5).

Key concepts and definitions (current understanding)
- SOCS5 is an intracellular adaptor/regulator that uses its SH2 domain to bind phosphotyrosine-bearing targets and its SOCS box to recruit CRL5 E3 ligase machinery, promoting ubiquitination and downregulation of signaling components; SOCS proteins can also inhibit JAK/STAT by receptor competition or JAK-association mechanisms. SOCS1/3 use an N‑terminal KIR to directly inhibit JAK catalytic activity; SOCS5 lacks a canonical KIR but negatively regulates cytokine signaling through receptor/JAK engagement and CRL5-mediated substrate ubiquitination (pilling2017cullin5andsocs pages 25-28, cianciulli2024inflammatoryskindiseases pages 3-5).
- Distinctive role in IL‑4/STAT6/Th subsets: SOCS5 associates with the IL‑4 receptor in a phosphorylation-independent manner to suppress STAT6 activation and Th2 differentiation; overexpression reduces Th2 development in vivo, positioning SOCS5 as a Th1-promoting/Th2-limiting factor (pilling2017cullin5andsocs pages 28-31, ghalehbaghi2024suppressorofcytokine pages 9-10).

Biochemical mechanism and pathway roles
- JAK/STAT inhibition modes: SOCS5 inhibits cytokine signaling by binding the IL‑4 receptor region and reducing downstream STAT6; mechanistically, SOCS proteins inhibit by (i) SH2-mediated competition at receptors, (ii) direct or indirect engagement with JAKs, and (iii) recruiting CRL5 via the SOCS box to ubiquitinate targets. SOCS5 shows evidence of negatively regulating JAK1/JAK2‑dependent outputs in context-specific settings, though without a KIR motif like SOCS1/3 (pilling2017cullin5andsocs pages 28-31, pilling2017cullin5andsocs pages 25-28, cianciulli2024inflammatoryskindiseases pages 3-5).
- CRL5 E3 ligase assembly: The SOCS box of SOCS5 binds Elongin B/C and couples to Cullin‑5/Rbx2, forming a CRL5 E3 ligase that promotes ubiquitination and proteasomal degradation of bound substrates, a central route for signal attenuation across the SOCS family (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).
- RTK regulation: SOCS4/5 are reported to regulate EGF receptor signaling; SOCS5 has been proposed to interact with EGFR via a phosphorylation‑independent mechanism through its N‑terminus/SH2 framework, placing it at the interface of growth factor and cytokine pathways (cianciulli2024inflammatoryskindiseases pages 3-5).
- PI3K pathway crosstalk: SOCS5 binds Shc (pY317) via its SH2 domain and associates with PI3K (p85/p110); SOCS5 depletion increases PI3K levels, suggesting SOCS5 impacts PI3K abundance and signaling complexes (pilling2017cullin5andsocs pages 28-31).
- Th cell polarization and IL‑4 signaling: Clinical and mechanistic data in chronic rhinosinusitis support a role for SOCS5 in Th lineage balance, with SOCS5 expression linked to Th1/Th17 axes and suppression of Th2 polarization via IL‑4R/STAT6 inhibition (ghalehbaghi2024suppressorofcytokine pages 9-10).

Cellular localization and recruitment dynamics
- SOCS5 is a cytosolic adaptor that is recruited to activated receptors or signaling intermediates via its SH2 domain; SOCS family proteins then engage CRL5 via the SOCS box to ubiquitinate bound substrates. Such recruitment underlies attenuation of cytokine/RTK signaling at the plasma membrane and endosomal compartments, though precise live-cell dynamics for SOCS5 remain less characterized than for SOCS1/3 (pilling2017cullin5andsocs pages 25-28, cianciulli2024inflammatoryskindiseases pages 3-5).

Recent developments and latest research (2023–2024)
- Pulmonary hypertension (2024): In a hypoxia-induced pulmonary hypertension model and in hypoxia‑treated human pulmonary arterial smooth muscle cells (HPASMCs), SOCS5 levels decline, and functional studies show that SOCS5 overexpression suppresses HPASMC proliferation, migration, contraction, and intracellular Ca2+ signals while inhibiting JAK2/STAT3 phosphorylation; SOCS5 knockdown has opposite effects. Mechanistically, miR‑155‑5p targets SOCS5 in this axis. GEO analysis also supports reduced SOCS5 in PH patient lung tissue (GSE15197). This identifies a miR‑155‑5p/SOCS5/JAK2/STAT3 regulatory axis in PH (BMC Pulmonary Medicine, Jan 2024, doi:10.1186/s12890-024-02857-6; https://doi.org/10.1186/s12890-024-02857-6) (sun2024socs5targetedby pages 5-9, sun2024socs5targetedby pages 1-2).
- Chronic rhinosinusitis (2024): In a cross-sectional human study, SOCS5 levels (mRNA/protein) differed between CRSwNP/CRSsNP cohorts and controls; SOCS5 correlated with Th17 in CRSsNP, and SOCS3 rose in CRSwNP. Findings support SOCS5 as a modulator of Th polarization in airway inflammation and a potential stratification biomarker (Yale J Biol Med, Jun 2024, doi:10.59249/hzfn2950; https://doi.org/10.59249/hzfn2950) (ghalehbaghi2024suppressorofcytokine pages 9-10).
- Immunology and infection (2024): A contemporary review highlights human/mouse data showing SOCS5 expression in T and B cells, its contribution to antiviral defense (SOCS5 deficiency increases early influenza A viral loads and disease severity), and clinical correlations (lower SOCS5 in COPD associated with elevated IL‑1β/TNFα), reinforcing SOCS5’s roles across cytokine/IFN networks (Frontiers in Immunology, Nov 2024, doi:10.3389/fimmu.2024.1449397; https://doi.org/10.3389/fimmu.2024.1449397) (lynch2024unravellingthedruggability pages 13-15, lynch2024unravellingthedruggability pages 15-16).
- SOCS family structure-function (2024): A review focused on SOCS druggability and structural biology reiterates SOCS family domain architecture and CRL5 coupling, and notes SOCS5’s negative regulation of IL‑4 signaling with limited development of direct SOCS5 modulators to date (Frontiers in Immunology, Nov 2024, doi:10.3389/fimmu.2024.1449397; https://doi.org/10.3389/fimmu.2024.1449397) (lynch2024unravellingthedruggability pages 13-15).

Current applications and real‑world implementations
- Inflammation and airway disease: Evidence positions SOCS5 as a negative regulator of IL‑4/STAT6 and JAK2/STAT3‑dependent responses in human airway and vascular smooth muscle contexts, suggesting potential for SOCS5‑centric strategies (e.g., restoring SOCS5 or blocking miR‑mediated suppression) to modulate Th2‑skewed or STAT3‑driven pathology (sun2024socs5targetedby pages 5-9, ghalehbaghi2024suppressorofcytokine pages 9-10).
- Biomarker potential: SOCS5 expression patterns in chronic rhinosinusitis subtypes and COPD correlations (lower SOCS5 with higher IL‑1β/TNFα) point to potential biomarker roles for inflammatory disease stratification and possibly prognosis (ghalehbaghi2024suppressorofcytokine pages 9-10, lynch2024unravellingthedruggability pages 15-16).
- General SOCS therapeutics landscape: While clinical translation has focused more on SOCS1/3 KIR‑mimetic peptides and JAK inhibitors, druggability analyses place SOCS family members as emerging targets and potential E3 handles. For SOCS5 specifically, translation is earlier-stage, with mechanistic disease associations guiding target validation (cianciulli2024inflammatoryskindiseases pages 3-5, lynch2024unravellingthedruggability pages 13-15).

Expert opinions and analysis from authoritative sources
- Structural/biochemical consensus: Reviews conclude that SOCS proteins, including SOCS5, function via SH2‑guided substrate recognition and SOCS box‑mediated assembly of CRL5 E3 ligases, forming a conserved negative feedback on cytokine/RTK signals. SOCS4/5’s prominence in EGFR/RTK pathways differentiates them functionally from SOCS1/3’s direct JAK blockade (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).
- Immunology perspective: Contemporary immunology review emphasizes SOCS5’s modulation of adaptive (Th polarization, IL‑4 axis) and innate/antiviral responses, with disease-relevant observations in COPD and viral infection models. The review also flags a relative paucity of SOCS5-targeted drug development compared with SOCS1/3 (lynch2024unravellingthedruggability pages 13-15, lynch2024unravellingthedruggability pages 15-16).

Relevant statistics and data
- Pulmonary hypertension model: In vivo hypoxia (4 weeks) increased RVSP and RVHI significantly versus normoxia, concomitant with decreased lung SOCS5 protein; in HPASMCs, SOCS5 overexpression reduced proliferation/migration/contraction and JAK2/STAT3 phosphorylation, while SOCS5 knockdown had opposite effects. SOCS5 mRNA showed a biphasic response to hypoxia (early increase at 3–6 h, decrease at 12–72 h), aligning with protein dynamics; GEO GSE15197 analysis showed reduced SOCS5 in PH patient lungs (BMC Pulmonary Medicine, Jan 2024; https://doi.org/10.1186/s12890-024-02857-6) (sun2024socs5targetedby pages 5-9, sun2024socs5targetedby pages 1-2).
- Chronic rhinosinusitis cohort: SOCS3 protein increased in CRSwNP vs CRSsNP and controls (p<0.05 to p<0.001), and SOCS5 levels differed between CRSsNP and controls with correlations to Th17 markers; data support differential SOCS expression across CRS endotypes (Yale J Biol Med, Jun 2024; https://doi.org/10.59249/hzfn2950) (ghalehbaghi2024suppressorofcytokine pages 9-10).

Open questions and limits
- Direct structural biochemistry of SOCS5 engagement with specific human receptors (e.g., IL‑4R cytosolic regions and EGFR) and definitive CRL5-dependent substrates remain areas for deeper mechanistic mapping in human systems compared with SOCS1/3. Live‑cell recruitment/localization kinetics for SOCS5 are less well resolved (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).

References (URLs and dates)
- Cianciulli A et al., Cells, Mar 2024. “Inflammatory Skin Diseases: Focus on the Role of Suppressors of Cytokine Signaling (SOCS) Proteins.” https://doi.org/10.3390/cells13060505 (cianciulli2024inflammatoryskindiseases pages 3-5).
- Pilling C. “Cullin5 and SOCS Protein Regulation of Receptor Tyrosine Kinases.” 2017. (general SOCS architecture and mechanisms) (pilling2017cullin5andsocs pages 25-28, pilling2017cullin5andsocs pages 28-31).
- Sun L et al., BMC Pulmonary Medicine, Jan 2024. “SOCS5, targeted by miR‑155‑5p, plays a negative regulatory role in pulmonary hypertension through inhibiting JAK2/STAT3 signaling pathway.” https://doi.org/10.1186/s12890-024-02857-6 (sun2024socs5targetedby pages 5-9, sun2024socs5targetedby pages 1-2).
- Ghalehbaghi B et al., Yale J Biol Med, Jun 2024. “Suppressor of Cytokine Signaling Proteins 3 and 5 Potentially Delineate Polarization of Th cells in Chronic Rhinosinusitis.” https://doi.org/10.59249/hzfn2950 (ghalehbaghi2024suppressorofcytokine pages 9-10).
- Lynch DM et al., Frontiers in Immunology, Nov 2024. “Unravelling the druggability and immunological roles of the SOCS-family proteins.” https://doi.org/10.3389/fimmu.2024.1449397 (lynch2024unravellingthedruggability pages 13-15, lynch2024unravellingthedruggability pages 15-16).

Conclusion
Human SOCS5 (UniProt O75159) is a SH2/SOCS‑box adaptor that attenuates cytokine and growth‑factor signaling by substrate recognition and CRL5‑mediated ubiquitination. Mechanistically, it suppresses IL‑4/STAT6 signaling and modulates JAK2/STAT3 outputs in disease settings, with emerging clinical associations in pulmonary hypertension and chronic rhinosinusitis, and correlations in COPD. While translational work has advanced more for SOCS1/3, recent analyses frame SOCS5 as a viable immuno‑regulatory target with potential therapeutic and biomarker applications, warranting focused efforts to define substrates, structural interfaces, and drugging strategies (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 28-31, sun2024socs5targetedby pages 5-9, ghalehbaghi2024suppressorofcytokine pages 9-10, lynch2024unravellingthedruggability pages 13-15).

References

1. (cianciulli2024inflammatoryskindiseases pages 3-5): Antonia Cianciulli, Rosa Calvello, Chiara Porro, Dario Domenico Lofrumento, and Maria Antonietta Panaro. Inflammatory skin diseases: focus on the role of suppressors of cytokine signaling (socs) proteins. Cells, 13:505, Mar 2024. URL: https://doi.org/10.3390/cells13060505, doi:10.3390/cells13060505. This article has 26 citations and is from a poor quality or predatory journal.

2. (pilling2017cullin5andsocs pages 25-28): C Pilling. Cullin5 and socs protein regulation of receptor tyrosine kinases. Unknown journal, 2017.

3. (sun2024socs5targetedby pages 5-9): Lili Sun, Lihua Liu, Dongxue Liang, and Linlin Liu. Socs5, targeted by mir-155-5p, plays a negative regulatory role in pulmonary hypertension through inhibiting jak2/stat3 signaling pathway. BMC Pulmonary Medicine, Jan 2024. URL: https://doi.org/10.1186/s12890-024-02857-6, doi:10.1186/s12890-024-02857-6. This article has 3 citations and is from a peer-reviewed journal.

4. (ghalehbaghi2024suppressorofcytokine pages 9-10): Babak Ghalehbaghi, Hossein Aazami, Majid Khoshmirsafa, Alireza Mohebbi, Pegah Babaheidarian, Nesa Rashidi, Kobra Mokhtarian, Reza Ahmadi, Monireh Kamali, Majid Ponour, Ayda Sanaei, Farhad Seif, and Maryam Jalessi. Suppressor of cytokine signaling proteins 3 and 5 potentially delineate polarization of th cells in chronic rhinosinusitis. The Yale Journal of Biology and Medicine, 97:165-177, Jun 2024. URL: https://doi.org/10.59249/hzfn2950, doi:10.59249/hzfn2950. This article has 2 citations.

5. (lynch2024unravellingthedruggability pages 13-15): Dylan M. Lynch, Beth Forrester, Thomas Webb, and Alessio Ciulli. Unravelling the druggability and immunological roles of the socs-family proteins. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1449397, doi:10.3389/fimmu.2024.1449397. This article has 8 citations and is from a peer-reviewed journal.

6. (pilling2017cullin5andsocs pages 28-31): C Pilling. Cullin5 and socs protein regulation of receptor tyrosine kinases. Unknown journal, 2017.

7. (sun2024socs5targetedby pages 1-2): Lili Sun, Lihua Liu, Dongxue Liang, and Linlin Liu. Socs5, targeted by mir-155-5p, plays a negative regulatory role in pulmonary hypertension through inhibiting jak2/stat3 signaling pathway. BMC Pulmonary Medicine, Jan 2024. URL: https://doi.org/10.1186/s12890-024-02857-6, doi:10.1186/s12890-024-02857-6. This article has 3 citations and is from a peer-reviewed journal.

8. (lynch2024unravellingthedruggability pages 15-16): Dylan M. Lynch, Beth Forrester, Thomas Webb, and Alessio Ciulli. Unravelling the druggability and immunological roles of the socs-family proteins. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1449397, doi:10.3389/fimmu.2024.1449397. This article has 8 citations and is from a peer-reviewed journal.

## Citations

1. cianciulli2024inflammatoryskindiseases pages 3-5
2. ghalehbaghi2024suppressorofcytokine pages 9-10
3. lynch2024unravellingthedruggability pages 13-15
4. lynch2024unravellingthedruggability pages 15-16
5. https://doi.org/10.1186/s12890-024-02857-6
6. https://doi.org/10.59249/hzfn2950
7. https://doi.org/10.3389/fimmu.2024.1449397
8. https://doi.org/10.3390/cells13060505
9. https://doi.org/10.3390/cells13060505,
10. https://doi.org/10.1186/s12890-024-02857-6,
11. https://doi.org/10.59249/hzfn2950,
12. https://doi.org/10.3389/fimmu.2024.1449397,